Evidence map›Paper›PMID 42633612›Full record

ArticleClinical transplantation2026

Effect of Pre-Transplant Sensitization on Kidney Allograft Survival Following Simultaneous Liver and Kidney Transplantation: A Decade of Experience from an Academic Transplant Center.

Andrew D Santeusanio, Fahima Mahir, Matias Facciuto, Ron Shapiro, Veronica Delaney, Thomas Schiano, Jang Moon, Sander Florman, Leona Kim-Schluger, Fasika Tedla and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrew D SanteusanioRecanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
Fahima MahirRecanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
Matias FacciutoIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Ron ShapiroRecanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
Veronica DelaneyRecanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
Thomas SchianoRecanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
Jang MoonRecanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
Sander FlormanRecanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
Leona Kim-SchlugerRecanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
Fasika TedlaRecanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.
Arjun BhansaliRecanati-Miller Transplantation Institute, Mount Sinai Hospital, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are conflicting data regarding the impact of pre-transplant sensitization on kidney allograft outcomes following simultaneous liver-kidney (SLK) transplantation.

methodsThis was a single-center, retrospective study of adult SLK transplant recipients during the decade from 2010 to 2020. Patients were classified based on complement dependent cytotoxicity crossmatching (CDC-CXM) as well as the presence of donor specific antibodies (DSA) and followed until study conclusion on January 1, 2021. Cox-proportional hazards modeling was performed to identify clinical variables associated with combined patient and allograft survival as well as biopsy proven kidney rejection (BPAR).

resultsA total of 90 patients were included in the study (16 positive CDC-CXM and 31 with DSA). Overall patient and allograft survival was 91.1% at 1-year and 68.9% at study conclusion after a median of 4.4 years, with corresponding death-censored kidney survival of 98.8% and 91.2%. In the multivariable analysis, a positive CDC-CXM (HR = 3.79; 95% CI 1.70-8.46) but not pre-formed DSA was associated with patient and graft loss. BPAR occurred in 12 patients (13.3%) and was higher among patients with DSA >5,000 (HR = 3.69; 95% CI 1.14-11.98), although this did not impact overall kidney survival. DSA cleared in 85% of patients following SLK transplant but persisted in three patients with DQ-specific antibodies.

conclusionsA positive CDC-CXM but not the presence of pre-formed DSA was associated with worse outcomes following SLK transplantation, with overall kidney survival primarily driven by death with a functioning allograft. DSA >5,000 MFI increased the risk for BPAR, and DSA to the class II DQ antigen were incompletely cleared following SLK transplant; however, overall kidney survival was not impacted.

Indexed as

Graft RejectionGraft SurvivalHistocompatibility TestingKidney TransplantationLiver TransplantationAdultAgedAllograftsBiopsyCombined Modality TherapyFemaleFollow-Up StudiesHLA AntigensHumansIsoantibodiesKidneyHLA AntigensIsoantibodiesgraft survivalkidney transplantationliver transplantationrisk factorssensitization

Identifiers

PMID42633612
PMCPMC13500032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.